Indian Wells

Researchers are evaluating a new care strategy for people at increased risk of atherosclerotic cardiovascular disease ASCVD but without symptoms. The study compares a Cleerly Coronary Artery Disease CAD Staging System-based care approach against the usual risk factor-based care to see if it better reduces cardiovascular events. This pragmatic, randomized trial addresses the need for improved methods to identify and personalize treatment for asymptomatic individuals at risk due to age, diabetes, prediabetes, or metabolic syndrome. Participants are randomly assigned to one of two groups. The risk factor-based care group receives usual care managed by their providers, while a cardiology team monitors and supports guideline-based treatment without revealing certain imaging results during the study. The Cleerly stage-based care group gets personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes imaging to assess coronary atherosclerosis and guides pharmacotherapy and education. Treatment intensity may increase if plaque worsens after 24 months. During the study, participants will have assessments to monitor heart health and treatment adherence over an average of 3.5 years. Researchers will measure cardiovascular events and other related health outcomes to compare the two care strategies. The study involves ongoing medication monitoring, lab tests, and feedback to optimize prevention, with the goal of improving personalized care for cardiovascular risk management.

Researchers are conducting the Phase I Human Analytics HALO Study to improve diagnosis and risk prediction for cardiovascular diseases, cancer, dementia, traumatic brain injury, and other disorders. The study uses machine learning and data analysis techniques on electronic medical records to detect subtle patterns, aiming to diagnose diseases earlier and more accurately. The research also focuses on developing multivariate biomarker risk scores and directing participants to relevant clinical trials based on physician review. This observational study involves no interventions and includes groups of patients diagnosed with dementia, prostate cancer, breast cancer, traumatic brain injury, and patients without any diagnosed condition. Data analysis will be applied to all available biomarkers and health determinants to enhance diagnostic confidence and reduce time to diagnosis. Participants are observed over time, with no treatments administered as part of the study. Participants will be monitored through clinical evaluations, biomarker assessments, and data analysis to assess prostate cancer staging, Gleason scores, and mortality over up to five years. Additional outcomes include measurements of urinary symptoms, erectile function, emotional well-being, and incontinence levels. The study collects comprehensive health data to improve diagnosis and risk stratification, with participant involvement lasting several years for long-term monitoring and evaluation.